

Acknowledgments. None.


Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. WHO director-general's opening remarks at the media briefing on COVID-19. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>. Published March 11, 2020. Accessed April 7, 2020.
2. Zhao Z, Zhang F, Xu M, *et al.* Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. *J Med Microbiol* 2003;52:715–720.
3. Wang D, Hu B, Hu C, *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–1069.
4. Yang X, Yu Y, Xu J, *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020. doi: [10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5).
5. Wang Y, Jiang W, He Q, *et al.* Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. *medRxiv* 2020. doi: [10.1101/2020.03.06.20032342](https://doi.org/10.1101/2020.03.06.20032342).
6. Zhao Z, Zhang F, and Xu M, *et al.* Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. *J Med Microbiol* 2003;52:715–720.
7. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim guidance by World Health Organization. [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected). Published March 13, 2020. Accessed April 7, 2020.
8. Tang NL, Chan PK, Wong CK, *et al.* Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. *Clin Chem* 2005;51:2333–2340.
9. Arabi YM, Balkhy HH, Hayden FG, *et al.* Middle East respiratory syndrome. *N Engl J Med* 2017;376:584–594.
10. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3:1525–1531.
11. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473–475.

Borderless collaboration is needed for COVID-19—A disease that knows no borders

Kawthar Mohamed^{1,2}, Eduardo Rodríguez-Román^{3,4}, Farzaneh Rahmani^{5,6}, Hongbo Zhang^{7,8}, Mariya Ivanovska^{9,10}, Sara A. Makka^{11,12}, Musa Joya^{13,14}, Rangarirai Makuku^{1,15}, Md Shahidul Islam^{16,17}, Nesrine Radwan^{18,19}, Laila Rahmah^{1,20}, Rayan Goda^{21,22}, Sunny O. Abarikwu^{23,24}, Mujtaba Shaw^{1,25}, Samaneh Zoghi^{26,27}, Sevan Irtsyan^{28,29}, Irene Ling^{30,31}, Orsolya Cseprekal^{32,33}, Attig-Bahar Faten^{34,35}, Esra Hazar Sayar^{36,37}, Chagajeg Soloukey^{38,39}, Giulia Grancini^{40,41} and Nima Rezaei^{1,42} 

¹School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, ²Universal Scientific Education and Research Network (USERN), Manama, Bahrain, ³Center for Microbiology and Cell Biology, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela, ⁴Universal Scientific Education and Research Network (USERN), Caracas, Venezuela, ⁵Washington University in St Louis, St Louis, Missouri, United States, ⁶Universal Scientific Education and Research Network (USERN), Missouri, United States, ⁷Pharmaceutical Sciences Laboratory and Turku Bioscience Centre, Åbo Akademi University, Turku, Finland, ⁸Universal Scientific Education and Research Network (USERN), Turku, Finland, ⁹Research Center, Department of microbiology and immunology, Medical University, Plovdiv, Bulgaria, ¹⁰Universal Scientific Education and Research Network (USERN), Plovdiv, Bulgaria, ¹¹Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon, ¹²Universal Scientific Education and Research Network (USERN), Beirut, Lebanon, ¹³Radiology Department, Kabul University of Medical Sciences, Kabul, Afghanistan, ¹⁴Universal Scientific Education and Research Network (USERN), Kabul, Afghanistan, ¹⁵Universal Scientific Education and Research Network (USERN), Harare, Zimbabwe, ¹⁶Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran, ¹⁷Universal Scientific Education and Research Network (USERN), Dhaka, Bangladesh, ¹⁸Allergy & Immunology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ¹⁹Universal Scientific Education and Research Network (USERN), Cairo, Egypt, ²⁰Universal Scientific Education and Research Network (USERN), Jakarta, Indonesia, ²¹Clinical Immunology and Allergy Council, Sudanese Society for Clinical Immunology and Allergy, Khartoum, Sudan, ²²Universal Scientific Education and Research Network (USERN), Khartoum, Sudan, ²³Department of Biochemistry, University of Port Harcourt, Choba, Nigeria, ²⁴Universal Scientific Education and Research Network (USERN), Choba, Nigeria, ²⁵Universal Scientific Education and Research Network (USERN), Kashmir, India, ²⁶Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria, ²⁷Universal Scientific Education and Research Network (USERN), Vienna, Austria, ²⁸Laboratory Service of Arakbir Medical Center, Yerevan, Armenia, ²⁹Universal Scientific Education and Research Network (USERN), Yerevan, Armenia, ³⁰School of Science, Monash University Malaysia, Jalan Lagoon Selatan, Selangor Darul Ehsan, Malaysia, ³¹Universal Scientific Education and Research Network (USERN), Selangor Darul Ehsan, Malaysia, ³²Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, ³³Universal Scientific Education and Research Network (USERN), Budapest, Hungary, ³⁴Universal Scientific Education and Research Network (USERN), Tunisia, Tunis, ³⁵University of Rostock, Rostock, Germany, ³⁶Alenya Training and Research Hospital, Pediatric Allergy Immunology Unit, Alanya, Antalya, Turkey, ³⁷Universal Scientific Education and Research Network (USERN), Antalya, Turkey, ³⁸Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands, ³⁹Universal Scientific Education and Research Network (USERN), Rotterdam, The Netherlands, ⁴⁰Physical Chemistry Unit, Department of Chemistry, University of Pavia, Pavia, Italy, ⁴¹Universal Scientific Education and Research Network (USERN), Pavia, Italy and ⁴²Universal Scientific Education and Research Network (USERN), Tehran, Iran

Author for correspondence: Nima Rezaei, E-mail: rezaei_nima@tums.ac.ir

Cite this article: Mohamed K, *et al.* (2020). Borderless collaboration is needed for COVID-19—A disease that knows no borders. *Infection Control & Hospital Epidemiology*, 41: 1245–1246, <https://doi.org/10.1017/ice.2020.162>

© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

To the Editor—Coronavirus disease 2019 (COVID-19) has become a global concern among all citizens and governments. Several governments have decided to take drastic actions to combat the spread of the disease, including closure of air, maritime, and land borders as an extreme measures of isolation. However, such measures have not prevented the disease from spreading globally; COVID-19 has already spread to almost all countries and regions, and the World Health Organization (WHO) named it a pandemic on March 11, 2020.¹ For this reason, some countries have announced a so-called 'lockdown.' This protocol includes, but is not limited to, the closure of all nonessential businesses, the obligatory physical isolation of all citizens through quarantine, social distancing for those that do go out of their homes, and public campaigns to encourage both frequent hand washing and refraining from touching the face.

Although these measures seem to be effective in 'flattening the curve,' they cannot be applied for a long because they have extreme economic consequences. Vivid examples of such detrimental economic consequences have occurred in Singapore and Hong Kong, where social distancing was applied meticulously. As soon as the measures were withdrawn, a second surge of the disease occurred.² So, what is the solution?

International collaboration seems to be the best tool for curbing the spread of SARS-CoV-2. This virus first hit more wealthy countries where resources and facilities were available, but even these wealthy countries failed to control it. SARS-CoV-2 knows no borders; it has reached every populated region on earth without discrimination. As SARS-CoV-2 spreads to countries with little or no sanitation, low or no hygiene, and few or no hospitals, the conditions could become extreme and dreadful. The prevention of this pending disaster is the role of every country on earth because this pandemic has no borders. Multinational, united efforts are required to end this crisis, which became evident when SARS-CoV-2 spread regardless of border closures. If wealthy countries do not support poor countries in curbing this viral infection, SARS-CoV-2 will find its way back to their countries.

In addition to the humanitarian goals of this collaboration, scientific collaboration is needed as well. The host's immune system has an important role in the transmission of SARS-CoV-2.³ Multiple severe cases within families also suggests a genetic predisposition to COVID-19.⁴ Thus, international collaboration to better understand the disease pathophysiology of COVID-19 is needed. In developed countries, telemedicine provides the opportunity for patients to communicate with physicians remotely via computer.⁵ However, such tools, as well as research, diagnostic kits, and vaccine manufacturers require a huge budget beyond a single country's financial capability.

This international collaboration should begin before SARS-CoV-2 spreads tragically through poor countries. This crisis is growing everywhere on our planet, and if we work together, we might find a solution. For example, a single poor country cannot afford to support test manufacturers. Now the crisis involves mostly rich countries, but what will happen when poor countries without adequate hygiene, sanitation, or well-equipped hospitals and facilities are affected? The consequences could be horrific, with an unimaginable toll.

We should start supporting these poor countries before the virus explodes among them. To refuse to come to their aid is cruel and against humanitarian and moral values. Also, if SARS-CoV-2 spreads uncontrolled, it is more likely to re-emerge in wealthy countries.⁶

The type of collaboration needed has happened before. The smallpox pandemic, a tragedy that killed ~2 million people in 1967, is one example. Nobody believed that the smallpox virus could be stopped, but eventually the goal was achieved, with an intense worldwide collaboration that took ~13 years (1967–1979). The smallpox eradication program was funded by the WHO and 42 other countries. The expense of this accomplishment was merely \$112 million in total, or an average of \$9 million per year over these 13 years. Some countries spent more individually to stop this pandemic, but their efforts were in vain.⁷ The global effort now needed to stop the COVID-19 pandemic should not be as difficult because of the internet as well as nongovernmental organizations such as the Universal Scientific and Educational Network (USERN), which connects scientists and students from >100 different countries.⁸

In conclusion, we may be wasting important time; a borderless solution for our complex COVID-19 problem could be the best solution overall. In addition to international scientific collaboration, the support of international organizations could help prevent an increase in cases, particularly in countries and regions where COVID-19 is in the early epidemic stage.

Acknowledgments. This letter is dedicated to the memory of all doctors and nurses who have fought and continue to fight against COVID-19 without any borders.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. WHO Director-General's opening remarks at the media briefing on COVID-19—11 March 2020. World Health Organization website. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020>. Published March 11, 2020. Accessed April 12, 2020.
2. Carlsson-Szlezak P, Reeves M, Swartz P. Understanding the economic shock of coronavirus. *Harvard Business Review* website. <https://hbr.org/2020/03/understanding-the-economic-shock-of-coronavirus>. Published March 27, 2020. Accessed March 27, 2020.
3. Saghazadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus—a perspective. *Expert Rev Clin Immunol* 2020 [Epub ahead of print]. doi: 10.1080/1744666X.2020.1750954.
4. Yousefzadegan S, Rezaei N. Death due to novel coronavirus disease (COVID-19) in three brothers. *Am J Trop Med Hyg* 2020 [Epub ahead of print]. doi: 10.4269/ajtmh.20-0240.
5. Moazzami B, Razavi-Khorasani N, Dooghaie Moghadam A, Farokhi E, Rezaei N. COVID-19 and telemedicine: immediate action required for maintaining healthcare providers well-being. *J Clin Virol* 2020 [Epub ahead of print]. doi.org/10.1016/j.jcv.2020.104345.
6. A global approach is the only way to fight COVID-19, the UN says as it launches humanitarian response plan. UNICEF website. <https://www.unicef.org/press-releases/global-approach-only-way-fight-covid-19-un-says-it-launches-humanitarian-response>. Accessed April 12, 2020.
7. Smallpox is dead. World Health Organization website. https://www.who.int/csr/disease/smallpox/WHO_RAS_SEP_ID0556_WorldHealth_May1980_ENG.pdf?ua=1. Published May 1980. Accessed April 11, 2020.
8. Rahmani F, Keshavarz-Fathi M, Hanaei S, *et al*. Universal scientific education and research network (USERN): step strong in scientific networking. *Acta Med Iran* 2019;57(1):1–4.